An observational study in Cardiac Allograft Vasculopathy, sponsored by German Heart Institute. Recruiting at 1 site in Germany. Per ClinicalTrials.gov, last updated 2024-08-12.
Sponsored by German Heart Institute · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The aim of the mCAV study is a comprehensive characterization of the genetic, morphological and functional phenotype of isolated microvascular graft vasculopathy (mCAV) after orthotopic heart transplantation (OHT).
The utilized methods include dynamic echocardiography, magnetic resonance imaging, invasive microvascular resistance measurements, histology, cellular calcium-signaling and magnetocardiography as well as molecular genetic expression analysis (miRNA based).
German Heart Institute is the lead sponsor of 25 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Heart transplant recipients
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Heart transplant recipients with microvascular cardiac allograft vasculopathy defined by histopathology and invasive index of microvascular resistance.
Diagnostic Test: Echocardiography · Diagnostic Test: Magnetic resonance imaging · Diagnostic Test: Magnetocardiography · Diagnostic Test: Histology · Diagnostic Test: Genetics · Diagnostic Test: calcium signaling · Diagnostic Test: IMR · Diagnostic Test: Angio-IMR
Heart transplant recipients without microvascular cardiac allograft vasculopathy defined by histopathology and invasive index of microvascular resistance.
Diagnostic Test: Echocardiography · Diagnostic Test: Magnetic resonance imaging · Diagnostic Test: Magnetocardiography · Diagnostic Test: Histology · Diagnostic Test: Genetics · Diagnostic Test: calcium signaling · Diagnostic Test: IMR · Diagnostic Test: Angio-IMR
Echocardiography with afterload change
Stress-MRI
Magnetocardiography
Histological analysis
miRNA sequencing
cardiomyocyte calcium signaling
Index of microvascular resistance measurement
Angiography derived post-processing index if microvascular resistance
mCAV status influences pw-doppler wall motion analysis in echocardiography
pw-doppler wall motion analysis is measured with afterload increase
Time frame: at study inclusion
mCAV status influences global longitudinal strain in echocardiography
global longitudinal strain is measured by speckle tracking analysis with afterload increase
Time frame: at study inclusion
mCAV status influences diastolic strain in echocardiography
diastolic strain is measured by speckle tracking analysis with afterload increase
Time frame: at study inclusion
mCAV status influences cardiac deformity
cardiac deformity analysis are performed by MRI
Time frame: at study inclusion
mCAV status influences grade of fibrosis
fibrosis grades are measured by MRI
Time frame: at study inclusion
mCAV status influences extracellular volume
extracellular volume is measured by MRI
Time frame: at study inclusion
mCAV status influences the circulating miRNA profile
circulating miRNA profile is measured by miRNAseq
Time frame: at study inclusion
mCAV status influences the intrinsic cardiac magnetic field
the intrinsic cardiac magnetic field is measured by magnetocardiography
Time frame: at study inclusion
mCAV status influences the cellular calcium signaling
the cellular calcium is visualized by confocal laser microscopy using electrical stimulation
Time frame: at study inclusion
mCAV status influences subcellular structures
mitochondria, T-tubuli are described after visualization by confocal laser microscopy
Time frame: at study inclusion
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2022 (actual). Primary completion is estimated for Dec 2025, 38 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
German Heart Institute